Results 91 to 100 of about 456,699 (237)

Immune checkpoint inhibitor-associated celiac disease

Journal for ImmunoTherapy of Cancer, 2020
Background Rare cases of immune checkpoint inhibitor (ICI)-associated celiac disease (ICI-CeD) have been reported, suggesting that disruption of tolerance mechanisms by ICIs can unmask celiac disease (CeD).
Jonathan Chen, Hui Zheng, Joseph Misdraji, Michael Dougan, Mari Mino-Kenudson, Meghan J Mooradian, Alexandra Coromilas, Yousef R Badran, Angela Shih, Donna Leet, Marina Kem, Jennifer Borowsky   +11 more
doaj   +1 more source

Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.

European Heart Journal, 2020
AIMS Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI). Sparse data exist on the use of cardiovascular magnetic resonance (CMR) in ICI-associated myocarditis.
Lili Zhang, Magid Awadalla, Syed S Mahmood, A. Nohria, Malek Z O Hassan, F. Thuny, Daniel A. Zlotoff, Sean P. Murphy, J. Stone, Doll Lauren Alexandra Golden, R. Alvi, Adam Rokicki, Maeve Jones-O’Connor, J. Cohen, L. Heinzerling, Connor P. Mulligan, Merna Armanious, A. Barac, Brian J. Forrestal, R. Sullivan, R. Kwong, E. Yang, Rongras Damrongwatanasuk, Carol L Chen, Dipti Gupta, M. Kirchberger, J. Moslehi, O. Coelho-Filho, S. Ganatra, M. Rizvi, G. Sahni, C. Tocchetti, V. Mercurio, M. Mahmoudi, D. Lawrence, K. Reynolds, J. Weinsaft, J. Weinsaft, A. Baksi, S. Ederhy, J. Groarke, A. Lyon, M. Fradley, P. Thavendiranathan, T. Neilan   +44 more
semanticscholar   +1 more source

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs

JAMA Network Open, 2020
This cross-sectional study estimates the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.
A. Haslam, J. Gill, V. Prasad
semanticscholar   +1 more source

PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature

Case Reports in Oncological Medicine, 2020
Background. Recurrent endometrial cancer after definitive therapy is a lethal disease. Recently, immune checkpoint inhibitors (ICI) have improved the management of mismatch repair-deficient (MSI-H) endometrial cancer. Autoimmune side effects are known to
Amanda Ramos, Marcela del Carmen, Oladapo Yeku   +2 more
doaj   +1 more source

Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. [PDF]

, 2019
The increasing number of patients with sequenced prostate cancer genomes enables us to study not only individual oncogenic mutations, but also capture the global burden of genomic alterations.
Bose, Rohit, Ryan, Matthew J
core   +1 more source

New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. [PDF]

, 2018
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. HCC initiates as a consequence of chronic liver damage and inflammation caused by hepatitis B and C virus infections, excessive alcohol consumption, or non ...
Karin, Michael
core   +1 more source

Immune checkpoint inhibitor–associated hypercalcaemia

Nephrology Dialysis Transplantation, 2020
AbstractImmune checkpoint inhibitors (CPIs) have recently become a cornerstone for the treatment of different advanced cancers. These drugs have the ability to reactivate the immune system against tumour cells but can also trigger a myriad of side effects, termed immune-related adverse events (irAEs).
Hassan, Izzedine, Thibaud, Chazal, Rimda, Wanchoo, Kenar D, Jhaveri   +3 more
openaire   +2 more sources

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. [PDF]

, 2016
Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters ...
Brzezniak, Christina, Cabrales, Pedro, Caroen, Scott, Carter, Corey A, Degesys, Aiste, Jenkins, John, Oronsky, Bryan, Peterson, P Gabriel, Quinn, Mary, Reid, Tony R, Schmitz, Bruno, Scicinski, Jan   +11 more
core   +4 more sources

Immune checkpoint inhibitors in malignancy [PDF]

Australian Prescriber, 2019
Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune systemInhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against themImmune ...
Luke, Ardolino, Anthony, Joshua
openaire   +2 more sources